Daniel T. Scavilla - Jul 2, 2021 Form 4 Insider Report for GLOBUS MEDICAL INC (GMED)

Role: EVP, Chief Commercial Officer
Signature: /s/ Kelly G. Huller, Attorney-in-Fact
Stock symbol: GMED
Transactions as of: Jul 2, 2021
Transactions value $: -$5,251,724
Form type: 4
Date filed: 7/7/2021, 04:46 PM
Next filing: Jan 31, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GMED	Class A Common Stock	Options Exercise	$1.28M	+50K		$25.52	50K	Jul 2, 2021	Direct
transaction	GMED	Class A Common Stock	Options Exercise	$1.31M	+50K	+100%	$26.27	100K	Jul 2, 2021	Direct
transaction	GMED	Class A Common Stock	Sale	-$7.81M	-99.6K	-99.6%	$78.41	400	Jul 2, 2021	Direct	F1, F2
transaction	GMED	Class A Common Stock	Sale	-$31.6K	-400	-100%	$78.97	0	Jul 2, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GMED	Stock Option (Right to buy Class A Common Stock)	Options Exercise	$0	-50K	-100%	$0.00^*	0	Jul 2, 2021	Class A Common Stock	50K	$25.52	Direct	F3
transaction	GMED	Stock Option (Right to Buy Class A Common Stock)	Options Exercise	$0	-50K	-62.5%	$0.00	30K	Jul 2, 2021	Class A Common Stock	50K	$26.27	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This sale was effected pursuant to a Rule 10b5-1 trading plan executed by the reporting person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.83 to $78.69, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3	These options were granted on January 25, 2016, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2017, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
F4	These options were granted on January 30, 2017, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2018, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.